EMEA-001710-PIP04-17-M03
Key facts
| Invented name |
Zeposia
|
| Active substance |
Ozanimod (hydrochloride)
|
| Therapeutic area |
Gastroentology-Hepatology
|
| Decision number |
P/0131/2022
|
| PIP number |
EMEA-001710-PIP04-17-M03
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of Crohn's disease
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Bristol-Myers Squibb Pharma EEIG
E-mail: medical.information@bms.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|